Outcome markers of ART-treated HIV plus patients with early stage Kaposi's sarcoma
Outcome markers of ART-treated HIV plus patients with early stage Kaposi's sarcoma
复制标题
DOI：
10.1371/journal.pone.0235865
复制
发表时间：
2020-07-07
期刊：
影响因子：
3.7
通讯作者：
West, John
中科院分区：
文献类型：
--
作者：
Ngalamika, Owen;Tso, For Yue;West, John
HIV-associated/epidemic Kaposi's sarcoma (EpKS) is an AIDS-defining angio-proliferative malignancy. It can be treated with antiretroviral therapy (ART) alone or with ART plus cytotoxic chemotherapy. ART-treated EpKS can either respond or worsen upon treatment. This study aimed at identifying immunological markers of ART-treatment response. We compared responders (those with clinical EpKS tumor regression) versus poor responders (those with progressive or non-responsive EpKS). We measured plasma cytokine and chemokine levels using cytometric bead assays. Kaposi's sarcoma herpesvirus (KSHV) neutralizing antibody (nAb) responses were also quantified to test associations with treatment outcome. Interleukin (IL)-5 levels were significantly elevated in responders versus poor-responders at baseline (0.76pg/mlvs. 0.37pg/ml; p
